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ABSTRACT
Introduction Time- critical neonatal trials in low- and- 
middle- income countries (LMICs) raise several ethical 
issues. Using a qualitative- dominant mixed- methods 
design, we explored informed consent process in 
Hypothermia for encephalopathy in low and middle- income 
countries (HELIX) trial conducted in India, Sri Lanka and 
Bangladesh.
Methods Term infants with neonatal encephalopathy, 
aged less than 6 hours, were randomly allocated to cooling 
therapy or usual care, following informed parental consent. 
The consenting process was audio- video (A- V) recorded in 
all cases. We analysed A- V records of the consent process 
using a 5- point Likert scale on three parameters—
empathy, information and autonomy. In addition, we 
used exploratory observation method to capture relevant 
aspects of consent process and discussions between 
parents and professionals. Finally, we conducted in- 
depth interviews with a subgroup of 20 parents and 
15 healthcare professionals. A thematic analysis was 
performed on the observations of A- V records and on the 
interview transcripts.
Results A total of 294 A- V records of the HELIX trial were 
analysed. Median (IQR) score for empathy, information and 
autonomy was 5 (0), 5 (1) and 5 (1), respectively. However, 
thematic analysis suggested that the consenting was a 
ceremonial process; and parental decision to participate 
was based on unreserved trust in the treating doctors, 
therapeutic misconception and access to an expensive 
treatment free of cost. Most parents did not understand the 
concept of a clinical trial nor the nature of the intervention. 
Professionals showed a strong bias towards cooling 
therapy and reported time constraints and explaining to 
multiple family members as key challenges.
Conclusion Despite rigorous research governance 
and consent process, parental decisions were heavily 
influenced by situational incapacity and a trust in doctors 
to make the right decision on their behalf. Further research 
is required to identify culturally and context- appropriate 
strategies for informed trial participation.
INTRODUCTION
Informed parental consent for time- critical 
trials in neonatal intensive care units (NICUs) 
is challenging, as parents are likely to be under 
extreme emotional distress due to the critical 
clinical condition of their newborn infant.1 In 
such situations, the clinical or research staff 
who approach parents for trial participation 
require specific training, skills and empathy 
to assist parents in making an informed and 
Key questions
What is already known?
 ► Informed parental consent for time- critical trials in 
neonatal intensive care units is challenging in high- 
income countries.
 ► Parental consent rates for neonatal intervention 
trials in low- and- middle- income countries are sub-
stantially higher than in high- income countries.
What are the new findings?
 ► Despite a rigorous informed consenting process, pa-
rental consenting was heavily influenced by an un-
reserved trust in the treating doctors and therapeutic 
misconception.
 ► Clinicians showed a clear bias favouring the inter-
vention (cooling therapy), which was reflected in 
their communications with the parents.
What do the new findings imply?
 ► Ethical boards and research teams need to be 
cognisant of the possibility of systematic bias and 
therapeutic misconception in emulating successful 
models of treatments from high- income countries to 
low- and- middle- income countries.
 ► Culturally appropriate and innovative approaches to 
trial recruitment and consent seeking are needed 
for time- critical trials conducted in low- and- middle- 
income countries.
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voluntary decision about their baby’s participation in a 
trial. The depth and level of information provided in 
the consenting process is expected to be proportionate 
to the potential for harm and the vulnerability of the 
trial population; for example, interventional trials may 
require more discussion than observational studies.2
Parental consent processes for time- critical trials in 
low- and- middle- income countries (LMICs) involving 
populations from lower socioeconomic backgrounds are 
even more complex due to low literacy levels, parental 
disempowerment, hierarchies that exist in healthcare 
setting and larger societal factors.3 4 Furthermore, the 
research governance and ethical frameworks in LMICs 
are less rigorous and may not adequately protect the trial 
participants.5 Expensive interventions that are not easily 
available outside a LMIC trial setting may misguide partic-
ipants by therapeutic misconception and false hopes.6–8 A 
recent systematic review comparing consent rates for 200 
randomly selected recent neonatal interventional trial 
demonstrated significantly higher parental consent rates 
in LMICs (95.5%) when compared with high- income 
countries (HICs) (82.7%), raising concerns about the 
credibility of the consent processes in LMICs.9
We conducted a mixed- methods nested study within 
the ‘Hypothermia for encephalopathy in low and middle- 
income countries (HELIX) trial’ to assess the rigour of 
the informed consent process and understand the factors 
influencing parental decision- making to participate in 
the trial.
METHODS
The HELIX trial ( ClinicalTrials. gov, NCT02387385), 
to which this mixed- methods study was linked, was an 
open- label, multi- country randomised controlled trial 
conducted in seven large public sector tertiary NICUs in 
India, Sri Lanka and Bangladesh. The trial was approved 
by the research ethics committees at Imperial College 
London and participating sites.
Prior to the trial launch, all the local clinical staff 
completed the International Conference on Harmonisa-
tionGood Clinical Practice certification and underwent 
rigorous training simulations on research ethics and 
informed consenting for the trial. There was specific 
emphasis during the training not to coerce parents into 
consenting for the trial by way of inducements such as 
financial benefits or specific investigations the baby may 
receive as a part of trial participation.
Between August 2015 and February 2019, parents of 
475 term infants requiring an emergency admission to 
the NICU within 6 hours of birth due to neonatal enceph-
alopathy were approached for trial participation.10 One 
of the neonatal physicians explained the trial procedures 
to the parents, shared a participant information leaflet 
(PIL) in the local language and then obtained written 
informed consent. Briefly, this included explaining the 
reason for conducting the trial, potential benefits and 
adverse effects of the intervention (cooling therapy), 
randomisation process, study investigations and the right 
to decline trial participation without affecting the baby’s 
clinical care in any way. Cooling therapy was adminis-
tered using an approved servo- controlled cooling device 
(Tecotherm Neo) costing UIS$15 000, if the infant was 
randomised to the intervention group. All trial proce-
dures were offered free of cost to all participants.
Audio- visual (A- V) recording of the consenting process 
was obtained in all cases to monitor that clinicians had 
provided all key information to parents, answered any 
questions they had and to ensure that parents were not 
coerced into consenting to the trial.
Study design and participants
We used a qualitative dominant mixed- methods design. A 
quantitative assessment of the A- V recordings of HELIX 
trial’s consent process was undertaken by two investiga-
tors (SP and MAE) who were not involved in the orig-
inal consenting process. A total of 294 A- V records of 
the HELIX trial which satisfied the quality parameters 
were analysed. Alongside, we used an exploratory obser-
vation method for capturing relevant aspects of consent 
process. Key observations and conversations between 
parents and professionals were noted down by SP and 
MAE independently.
A subgroup of the 20 consecutive parents who had 
their child’s neurodevelopmental outcome assessments 
between August and September 2020 were invited to 
participate in a semi- structured in- depth interview, close 
to their clinical assessments at 18 months. Participants 
were recruited through purposive sampling; location 
(study sites) was considered to obtain diversity in narra-
tives and experience. Parents from Bangladesh could 
not be interviewed due to language barrier and logis-
tical issues. We interviewed medical and nursing teams 
(n=15) who were involved in the recruitment at all trial 
sites (figure 1).
Parental interviews explored their experiences prior 
to and after the birth of their baby, their decision of 
trial participation, understanding of the trial proce-
dures and their overall experience of participation. 
Professional’s interviews were focused on the informed 
consent process, challenges faced during the process and 
their overall experience of recruiting to a time- critical 
neonatal randomised controlled trial. A total of 10 inter-
views were conducted face to face and 24 over telephone. 
The sample size was determined by data saturation, that 
is, at the point at which no new information or theme was 
observed in the data.11 The interviews were conducted 
by a female qualitative researcher (MAE). All interviews 
were audio recorded, translated and transcribed verbatim 
for analysis. NVivo V.12 software was used to organise and 
manage interview data.
Data analysis
The A- V recordings of the original consent process 
were scored using a predefined proforma with 18 ques-
tions under 3 domains: (a) empathy12 (ie, respectful 
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communication in local language and avoidance of 
medical jargon), (b) information (ie, explanation of all 
study procedures and risk benefits) and (c) autonomy13 
(refer online supplemental file - annexure 1). Each 
question was scored using a 5- point Likert scale from 1 
(lowest) to 5 (highest); median and IQR were calculated.
Interviews were analysed thematically, which involved 
reading the transcripts several times to identify, analyse 
and report the themes within and across the data.14 15 
Analysis was broadly interpretive, and themes were induc-
tively derived from the data. Constant comparative 
method was used to generate validity of data with an 
objective to inform ethical governance and guidelines in 
LMIC trials.16 SP and MAE conducted line- by- line coding 
of transcript and developed initial codes. Observation 
notes were also analysed thematically, which helped SP 
and MAE to reflect on interview findings and further 
refine the coding framework (refer online supplemental 
file - annexure 2). Finally, visual thematic maps were 
developed to conceptualise themes and find common-
alities and the interdependence within these themes 
through an iterative process of concurrent reflection and 
discussion.
Ethical considerations
Ethics approval for HELIX trial and the mixed- methods 
study was obtained from Imperial College Research 
Ethics Committee. The approvals included A- V recording 
of the consent process, review of A- V records as well as 
in- depth interviews with parents and professionals. The 
study objectives and voluntary nature of the study were 
explained to the participants and informed consent was 
obtained prior to the interviews.
Patient and public involvement statement
Parent representatives from LMICs advised designing of 
HELIX trial as well as the PIL, although they were not 
directly involved in the design of the current study.
RESULTS
A total of 475 parents were approached, and 408 (86%) 
agreed to participate in the HELIX trial. Of these, 
123 (30%) infants were born in the trial centres while 
285 (70%) were either born in another facility or had 
home birth. The mean (SD) time from admission to the 
neonatal unit to consenting was 113 (97) min. Following 
Figure 1 HELIX trial consent flow chart.
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parental consent, 202 infants were randomised to cooling 
and 206 to usual care.
Analysis of A-V consent recordings
Semi-quantitative assessments
For HELIX trial, a total of 408 A- V records of parental 
consents were obtained in seven different South Asian 
regional languages. Neonatal consultants or the site prin-
cipal investigator obtained the consent in 12% cases, 
and junior doctors in 88% cases, although this varied by 
the centre. Among these consent taking professionals, 
53% were male and 47% were female. In most cases 
(89.3%), fathers were involved in consenting, followed 
by mothers (4.6%), both parents (3.1%) and relatives 
(3.1%). Mothers, when present, were passive observers, 
while fathers or other male family members present (in 
absence of the father) were seen engaging in discussions 
with the clinicians and making decision regarding child’s 
enrolment to the trial.
Due to issues such as loss of data and poor quality of 
audio, we were able to analyse a total of 294 A- V recordings 
from six centres. Mean (SD) duration of A- V recordings 
was 10.3 (7.2) min. Parents were briefed about key study 
information including randomisation, cooling therapy 
and risk–benefits in all cases. The information that was 
not discussed during the consent process included data 
confidentiality (12%), regulatory approvals (10%), addi-
tional blood tests and umbilical cord histology (9%), 
and the freedom to withdraw from the study at any time 
without the clinical care being affected (6%).
Semi- quantitative analysis based on the 17 predefined 
categories showed median (IQR) score for empathy, 
information and autonomy of 5 (0), 5 (1) and 5 (1), 
respectively, indicating an excellent informed consenting 
process. The consent quality scores of day- time and night- 
time recruits, and those obtained by the consultants and 
junior doctors were similar (p>0.05) (figure 2).
Thematic analysis of the A-V recording
The following themes were identified on careful obser-
vation of the A- V recordings of the consenting process.
A ceremonial process
In most cases across study sites, the clinicians read out 
the PILs and parents rarely sought clarifications or asked 
questions. In most of the video records, clinicians were 
observed using phrases such as ‘as I explained earlier’ and 
‘as discussed with you’, which indicated that the videos did 
not necessarily represent the first trial discussion with a 
family. The whole process appeared ceremonial; a task 
that needed to be fulfilled as per the trial protocol. Thus, 
the A- V recordings appeared to be a re- affirmation of the 
earlier discussion between the clinicians and the family.
Clinician’s bias towards the intervention (cooling therapy)
Instances were observed where clinicians and research 
nurses were not in equipoise and referred to the trial 
treatment as something beneficial, which could help 
improve their baby’s outcome. As the following quotations 
illustrate, in some cases, clinicians highlighted access 
to free treatment through trial participation or made 
unsupported assurances about safety of cooling in this 
LMIC setting.
“It is your luck that you are here, outside for this treatment, 
you have to spend a lot of money. Here it is given free of 
cost”—Research nurse (Video analysis_355)
“Cooling will not cause any side effects, it is a proven 
treatment, and you need not worry about it”—Clinician 
(Video analysis_29)
Disempowerment and trust in doctors to do ‘what was best’
Many parents seemed visibly distressed during recorded 
discussions and there were instances where fathers broke 
down during the consent process. In many record-
ings, parents told the doctor that they lacked sufficient 
knowledge to decide about trial participation and made 
requests for the doctor to do whatever they felt was best 
for their baby.
“We don’t know much, you know everything cos you are 
qualified, please see the baby and do whatever is necessary, 
they [referring centre] sent us here saying it will be good 
for the baby” (Video analysis_5)
“If you say so, it is fine, I will sign the paper. You know 
better as you are a doctor. We don’t even know A,B,C,D of 
this; we completely trust you and rest is up to God” (Video 
analysis_19)
Analysis of the interviews with parents
A total of 20 parents were approached for the interviews 
and all of them consented to participate. Of these inter-
views, only fathers participated in 14, both parents in 
Figure 2 Distribution of the Likert scores under the three 
domains. Red dots indicate consent obtained during normal 
working hours (8:00 to 18:00) and black dots indicate 
consents obtained out of hours (18:00 to 20:00).
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five and only mother in one. Parent profile is presented 
in table 1. Key themes developed from interviews with 
parents are given in the next section.
Limited understanding about the concept of a clinical 
trial and intervention: “Baby was kept on a machine”
Despite AV recordings confirming that adequate infor-
mation was provided to parents, interview findings indi-
cated that most parents did not understand that they were 
participating in a clinical trial; parents felt that it as an 
additional treatment, for which they had to give consent. 
Many of them explained the trial as ‘treatment was done 
using a machine’ and that the treatment was provided by a 
‘team from London’.
“The doctor told there is a chance for the baby to have 
some issues with the development, and his brain is weak, 
he needs to be put on the machine and his report will be 
sent to London and do you agree to do this. So I said yes 
and we agreed”—P4(3).
“When I came there they told that the baby is in a critical 
condition, there is a machine, they will keep the baby in 
the machine and computer will decide if the baby can be 
given this treatment or not”—P4(2).
Making decisions under pressure: “We just wanted our 
baby to survive”:
While reflecting on the decision to enrol their baby in 
the trial, most parents said that they were anxious and 
under tremendous pressure to decide about trial partic-
ipation due to their baby’s critical condition. Many felt 
incapacitated by the situation, as they did not have any 
other option, but ultimately hoped that their child would 
survive.
“We were in great tension [stress], we were scared… we 
were thinking if this treatment will work or not, we were 
really worried, but what to do, we didn’t have any other 
option. We just wanted the best treatment to be done”—
P2(3).
“That time we did not think much about the treatment we 
were only worried about the critical condition of our baby, 
and that she should get better. We did not think about any-
thing else at that time”—P3(1)
Some accounts indicated that the unfamiliar hospital 
environment increased levels of fear and incapacity to 
make an informed decision. One father struggled to 
recall any details about the research, apart from how 
doctors reassured them that their child would survive if 
they took part in the trial.
“I don’t have any idea, I don’t know why they kept him. We 
were very scared we are from village and we don’t know 
anything about the hospital. I had gone for the first time 
and they kept saying that we have to do this for the baby 
and the baby will be alright and then we just told yes. We 
were really scared but still we told him to go ahead because 
our baby has to become alright”—P1(3)
Cost concerns: “We did not have the money to go to 
private hospitals”:
Treatment cost was another important factor which 
influenced parental decision- making. A few parents 
shared that they decided to participate in the trial once 
they learnt that the treatment and hospital care was 
offered free of cost.
“I said okay for everything… our friends told in [name] 
hospital and other private hospitals it [cooling therapy] 
will be about INR 4,00,000; in [name] hospital, it will be 
more than INR 10,00,000, but luckily the bed was available 
here”—P8(1)
“I didn’t have much money to go to the private, and when 
poor people like us go to the government hospital, we just 
trust God and then trust doctor. We are not rich, we are 
poor, so we told go ahead, we agree to what you are sug-
gesting”—P3(3)
Trust in treating doctors: “The doctors will do what is 
good”
Parents had unreserved trust in doctors to do whatever 
was necessary to save their child’s life. Many appeared 
to believe the recruiting doctors were in a better posi-
tion to decide about their own child’s trial participation. 
Parents described how they encouraged the doctor to do 
what they thought was appropriate by ‘letting the doctor 
get on with it’ without fully understanding what the trial 
entailed. Although PIL and most of the communication 
were in the local language, use of certain medical termi-
nologies in English further limited their understanding 
of what the trial involved.





Age (in years) 20–30 4
  31–40 14




  High school 10
  Higher- secondary 4
  Undergraduate 4
Occupation* Unemployed 1
  Skilled worker 10
  Semi- skilled worker 2
  Professional 1
  Self- employed 5
Monthly income
(INR and USD)
<10 000 (<US$140) 4
  <20 000 (<US$285) 11
  <30 000 (<US$420) 2
  >30 000 (>US$420) 3
Semi- skilled workers included office helper, security personnel etc.
*Skilled workers included carpenters, drivers, mechanics, 
electricians, tailors etc.
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“I told the doctor to save my baby, whatever you feel ap-
propriate you please do it. You are telling many things 
in English about medical things and I don’t understand 
those, but whatever you want to do, please go ahead with 
it”—P4(2)
“When the doctor says something, we will trust it 99%. We 
just assume that they are doing a good job and we let them 
do it”—P8(1)
Parents’ belief in positive treatment outcomes: 
“Because we did this, baby is okay”
Although the whole trial recruitment process was 
described to be quite stressful and confusing, most 
parents believed that their babies had a better outcome 
due to the machine treatment, and referred to their 
babies being ‘alright’, irrespective of adverse neurodevel-
opmental outcomes.
“I believed the doctor’s advice and now the baby is alright. 
At that time the advice given by the doctor satisfied me”—
P3(2) (the child has cerebral palsy)
“Definitely the treatment has benefitted the baby. It was 
good, this treatment has to be given to more people”—
P8(1) (the child has delayed speech development)
Analysis of interviews with professionals
A total of 15 professionals were contacted and all of them 
consented to participate in the study. Of these, nine were 
neonatal trainees, two were consultants, and four were 
research nurses (RN) who assisted the recruitment and 
consent process (table 2). Key themes developed from 
interviews with professionals are shared in the next 
section.
Hesitation to use the term ‘trial’
Clinicians shared that they were comfortable in explaining 
or proposing the treatment and trial participation to 
parents as the treatment is a standard of care in most 
Western countries. Some expressed that they used the 
word ‘study’ and not ‘trial’ as they worried parents may 
consider this as an ‘experimentation on babies’ and may not 
agree to participate.
“We were really worried about what would be the response 
initially… we didn’t want to sound like they are some ex-
perimental guinea pigs; we were saying that it is a standard 
of care [in the UK], it is a study and it is well researched 
all over the world and we want to bring it to our country. I 
think the way you word it is very important, if you just tell 
them that it is part of a trial or a study then they may be 
worried”—Clinician 1(4)
Limited parental understanding about randomisation
Clinicians described how most parents were from low 
socioeconomic backgrounds and had minimal levels of 
education. They believed it was often difficult for parents 
to comprehend their baby’s condition, as well as invi-
tations to participate in the trial and details of the trial 
procedures. The concept of randomisation was described 
as being particularly difficult for parents to understand, 
with many parents insisting that their baby should receive 
cooling therapy, despite their babies being randomised 
to the control arm.
“Those who are a little more educated they probably un-
derstand what is happening better than who are living on 
the streets and less educated or doing some menial labour. 
Such parents could not understand, it was difficult for 
them to understand what was happening”—Clinician 1(3)
“Some parents would ask when the randomisation comes 
in the non- cooling arm, if there a possibility to do the cool-
ing—such type of questions a few parents would ask. We 
will explain to them that whichever arm the randomisation 
comes to, we will be forced to do that and we will not be 
able to change it according to their wish”—Clinician 2(2)
Requests were perhaps unsurprising. The following quotes, 
as well as parent interview findings, suggest that parents’ 
requests to be allocated to the intervention arm appear to 
have been influenced by clinicians presenting the hypo-
thermia treatment as proven to be beneficial for their baby.
“I think the main challenge was to explain to them about 
the concept of randomisation. That is the one thing they 
did not understand, ‘You told me that hypothermia is very 
beneficial and suppose by randomisation my baby doesn’t 
get it, then I am having a loss’, they would say”—Clinician 
2(3)
“I wasn’t uncomfortable [taking consent] because it was 
not an experimental study or anything it is already a proven 
treatment. In western countries and many of the hospitals 
are doing it already. If you go to corporate hospitals, they 
will do it”—Clinician 1(1)
Time pressure due to the narrow window period of 
recruitment
Within the limited therapeutic window of cooling 
therapy, clinicians often had less than an hour to counsel 
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the parents about their baby’s condition, explain the trial 
and seek their consent. The pressure was multi- fold in 
cases where parents were not available to consent at the 
time of admission, as in case of outborn infants.
“Sometimes they would reach at 4 to 5 hours and then you 
have only one hour left within the time window. We have 
had one or two instances where we have started the process 
in just 10 minutes before the time period, time frame… 
So that was a challenge when they come from the far- off 
places”—Clinician1(4)
Many shared the view that such a short time was not 
enough for the parents to understand everything about 
the trial, especially considering their emotional distress.
“What I felt was most parents were in an emotional state to 
understand… asphyxia is an unexpected event. When they 
are referred from another hospital, it takes some time for 
this to sink in. We tell them that it is the study going on but 
sometimes it takes time for them to understand what really 
is happening”—Clinician1(4)
A few clinicians shared that owing to the parents’ 
requests, they often had to explain the trial information 
to multiple family members, and relatives, which further 
magnified time constraints.
“We have to explain individually like to 10 people, the 
same process again and again”—Clinician2(3)
Misinformation given by referring centres
Clinicians reported how the complexities of explaining 
the trial to parents grew multi- fold when they were 
referred from peripheral centres with inaccurate expla-
nations and expectations about the trial.
“They [the referring centre] wouldn’t have told them that 
there is 50% chance of either cooling or standard care. 
They would have just told that this is a new treatment and 
it is available in [hospital name]… please go, if you keep 
the baby here we are not sure what is going to happen. 
So many times they have come with that hope without any 
background knowledge”—Clinician 2(1)
“But one bad impact was there, some people just told that 
this is the new machine and you report over there, the baby 
will be cooled down”—Clinician2(5)
Parental anxiety about A-V recording
While clinicians described the video recording as a 
good practice for standardising the informed consent 
process, it was a challenge logistically and often parents 
were apprehensive. Parents perceived that the treatment 
may not be safe and their consent to participation was 
recorded due to the risky nature of the trial. Due to this 
misguided belief, consent process was multi- layered and 
more time consuming, whereby clinicians would first 
inform parents about the trial, as well as video consent, 
clarify their queries and then be able to conduct the 
consent process again for the purpose of the video.
“Sometimes when we start video recording, they used to 
think—they are recording, and something is happening… 
they used to ask why you have to take a video like that. So, 
we used to explain to them that the video consenting is the 
ultimate form of consent”—Clinician 1(1)
“Something like this which is time critical and in a very 
emotionally charged situation… you’re trying to get the 
consent, in our set up, we can’t walk into the labour room 
with a video camera and then start the process. We have to 
formally say that we are going to do it with a written consent 
and then we do a video consent later on”—Clinician1(6)
DISCUSSION
In this study, we describe the unique complexities and 
challenges of informed consenting and the parental 
and professional perspectives of research participation 
in LMICs. Proforma- based quantitative analysis of A- V 
recordings suggested an elaborate consent process, 
where parents were provided adequate information prior 
to recruitment, including randomisation, potential risks–
benefits and parental autonomy in decision to participate 
in the trial. On the contrary, observational analysis from 
A- V recordings clearly revealed clinician’s bias towards 
cooling therapy, and emotional distress and disempow-
erment of parents.
Parental interview findings were consistent with these 
observations. Decision to participate was primarily based 
on the trust in the treating doctors, and therapeutic 
misconception, and the opportunity to have an expen-
sive treatment free of cost. Most parents did not under-
stand the concept of a clinical trial nor the nature of the 
intervention. Lower levels of parental education and 
misinformation provided by the referring centres further 
convoluted the voluntary informed consent process. 
Interviews with professionals reiterated the strong bias 
towards cooling therapy, as this was already a standard of 
care in HICs and many LMIC hospitals in private sector. 
Time constraints and explaining to multiple family 
members were reported as the key challenges faced by 
professionals. In a situation of extreme distress, a posi-
tive validation of cooling therapy from professionals was 
a ‘ray of hope’ for parents. Therefore, parental decisions 
were not entirely autonomous and were influenced due 
to situational incapacity and a trust in doctors to make 
‘the right decision on their behalf’.
Cooling therapy is recommended by the International 
Liaison Committee Resuscitation guidelines in 2015 as 
the standard of care in LMICs for neonatal encephalop-
athy.17 Although the guidelines acknowledged the poor- 
quality evidence regarding safety of cooling therapy in 
LMICs, it was already implemented in many NICUs in 
India18 and other South Asian countries19 as standard 
care, at the time of the HELIX trial recruitment. Hence, 
the bias of the clinicians towards cooling therapy during 
consenting is understandable. At the time of undertaking 
the qualitative study, HELIX trial was still ongoing, and 
hence clinicians were not aware of the trial outcomes. 
The trial has now been concluded and, contrary to the 
clinicians’ views, the results showed cooling therapy 
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significantly increased mortality and offered no neuro-
protection to infants in these settings.20 While these 
results were rather unexpected, it underlines the primary 
purpose of conducting any clinical trial—that is, to find 
out if a new treatment is beneficial or not. HELIX trial has 
reiterated the danger of directly extrapolating the results 
of research from high- income to low- income settings.
In HICs, research without prior consent has recently 
emerged as the preferred approach in time- critical trials, 
which allows the investigator to proceed with recruitment 
when treatment is required urgently and prior consent is 
not feasible.21 22 Some trials have sought parental assent 
prior to enrolment followed by a detailed informed 
consent to account for the emotional distress that parents 
experience affecting their ability to make informed deci-
sions.23 However, in our view, research without prior 
parental consent is not an appropriate option in LMICs 
due to lack of rigorous research governance in these 
settings. Serious concerns have been reported time and 
time again about the adequacy of informed consenting 
processes in pharmaceutical- sponsored paediatric clin-
ical trials in India.24–26 This issue prompted the Indian 
government to tighten regulatory approval of research 
and to mandate A- V recording of the informed consent 
process.27 While this was a step in the right direction, these 
regulations were subsequently removed by the Govern-
ment of India due to the difficulties in obtaining such 
A- V recordings. Recent controversies about COVID-19 
vaccination trials in India using financial incentives and 
inadequate informed consenting had led to international 
condemnation of the research governance.28 These 
malpractices are not uncommon in LMICs and therefore 
warrant a robust review and an oversight mechanism to 
protect vulnerable participants.
While our study provides useful insights into the 
consenting process followed in a neonatal time- critical 
trial in LMICs, it has certain limitations. First, although 
interview findings were supported by observations of 
A- V recordings and clinician accounts, parent interviews 
were conducted at follow- up visits approximately 18 to 22 
months after original consenting and recruitment, which 
is likely to have impacted on recall. To minimise the recall 
bias, we interviewed parents who were recruited towards 
the end of trial. Second, information on parent’s socio-
demographic information was not captured in HELIX 
trial. However, there is no reason to believe that the 
study sample of 20 parents is not a representative sample 
since recruitment was done consecutively. Third, in most 
cases the A- V recording seems to be done as a second 
or third layer of consenting, which precludes insight 
into initial recruitment discussions. The professionals 
reported that it was not easy for them to convince the 
parents to appear on the video recording and it required 
detailed explanation of the trial purpose and importance 
of recording the consenting process. They also reported 
that in certain cases where the baby was brought in at 
the very last minute, clinicians did not have the window 
to video record the consent. In such instances, A- V 
recording was done after the baby had been recruited to 
the trial. Hence, the analysis of consent videos may not 
have been a true depiction of consent process in all cases. 
Moreover, we interviewed only the parents of infants who 
survived. It is possible that those who had lost their infant 
had a different experience of trial participation. Finally, 
our study demonstrated an inadvertent contradiction 
between proforma assessments of A- V recordings and 
the observational as well as interview data highlight the 
inadequacy of quantitative assessments in such complex 
research questions and the need for in- depth qualitative 
enquiry to understand the rigour of consent processes in 
LMIC trials.
Better models for empowering parents and obtaining 
informed consent in LMIC needs to be carefully 
addressed in future trials. Innovative approaches using 
infographics and videos to communicate different 
aspects of trial may improve participant understanding 
and reduce anxiety,29 30 and such techniques may facili-
tate better informed consent in LMICs. Involving parents 
and family members in the design of studies would help 
in understanding their perspectives and addressing their 
priorities.
CONCLUSION
Our findings highlight the challenges of obtaining a truly 
informed consent in LMICs, despite having a rigorous 
protocol for seeking consent as well as regular quality 
assurance audits. Extremely vulnerable and disempow-
ered parents who lacked capacity to understand trial 
information and make an autonomous decision were 
influenced by the way the trial was presented to them. 
Lack of clinician equipoise and trial outcomes suggest 
that ethical boards and research teams need to be 
cognisant of the possibility of systematic bias and thera-
peutic misconception in emulating successful models of 
treatments from HICs to LMICs. Given the direct bene-
fits of enhanced care anticipated by participants and 
their immense faith in the medical team, more efforts in 
finding culturally appropriate and innovative approaches 
to trial recruitment and consent seeking are needed for 
time critical trials conducted in LMICs.
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